In April, new shareholders such as Bayland Capital, Huajin Avenue were added, with an investment amount of nearly 200 millions of RMB.
In June, Trinomab Completed Share Reform and renamed as Zhuhai Trinomab Pharmaceutical Co., Ltd. In October , Trinomab’s TNM009 and TNM005 Entered Phase I Clinical Trial.
In December, A first-in-class anti-tetanus monoclonal antibody TNM002 in the world is filed for NDA.
In March, TNM002 obtained breakthrough drug certification. In November, Trinomab annunces Initiation of Phase III Clinical Trial for Its Prophylactic Antibody against Tetanus Toxin. In November,completed approximately 750 Million RMB Pre-IPO Round Financing.
In April, the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million. In August, completed Round A+ Financing of RMB 700 million.
In November, the world's first fully human monoclonal antibody against tetanus toxin, developed independently, entered phase I clinical trials.
In April, reached a strategic cooperation agreement with WuXi Biologics. In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.
In September, completed Pre-A round of financing of RMB 200 million.
In May, the fully human monoclonal antibody new drug development center was put into operation.
In September, selected as an Innovation and Entrepreneurship Team in Zhuhai.
On December 17, Trinomab Biotech Co., Ltd was officially registered.
In April, new shareholders such as Bayland Capital, Huajin Avenue were added, with an investment amount of nearly 200 millions of RMB.
In June, Trinomab Completed Share Reform and renamed as Zhuhai Trinomab Pharmaceutical Co., Ltd. In October , Trinomab’s TNM009 and TNM005 Entered Phase I Clinical Trial.
In December, A first-in-class anti-tetanus monoclonal antibody TNM002 in the world is filed for NDA.
In March, TNM002 obtained breakthrough drug certification. In November, Trinomab annunces Initiation of Phase III Clinical Trial for Its Prophylactic Antibody against Tetanus Toxin. In November,completed approximately 750 Million RMB Pre-IPO Round Financing.
In April, the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million. In August, completed Round A+ Financing of RMB 700 million.
In November, the world's first fully human monoclonal antibody against tetanus toxin, developed independently, entered phase I clinical trials.
In April, reached a strategic cooperation agreement with WuXi Biologics. In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.
In September, completed Pre-A round of financing of RMB 200 million.
In May, the fully human monoclonal antibody new drug development center was put into operation.
In September, selected as an Innovation and Entrepreneurship Team in Zhuhai.
On December 17, Trinomab Biotech Co., Ltd was officially registered.
